Skip to main content
Top
Published in: Drugs in R&D 4/2008

01-07-2008 | Review Article

Adaptive Clinical Trials

Progress and Challenges

Authors: Dr Christopher S. Coffey, John A. Kairalla

Published in: Drugs in R&D | Issue 4/2008

Login to get access

Abstract

Adaptive designs promise the flexibility to redesign clinical trials at interim stages. This flexibility would provide greater efficiency in drug development. However, despite this promise, many hesitate to implement such designs. Here we explore three possible reasons for the hesitation: (i) confusion with respect to the definition of an ‘adaptive design’ (ii) controversy surrounding the use of sample size re-estimation methods; and (iii) logistical barriers that must be overcome in order to use adaptive designs within existing trial frameworks.
The large volume of recent work has created confusion with respect to the definition of an ‘adaptive design’. Unfortunately, this has resulted in reduced usage of many acceptable methods because of guilt by association with the more controversial methods. This review attempts to clarify the differences among many common types of proposed adaptive designs. Once the differences are noted, it becomes apparent that some adaptive designs are well accepted while others remain very controversial. In fact, much of the controversy and criticism surrounding adaptive designs has focused on their use for sample size re-estimation. Hence, this review also examines the different types of adaptive designs for sample size re-estimation in order to clarify the controversy surrounding the use of these methods. Specifically, separating the controversial from good practice requires clarifying differences between adaptive designs with sample size re-estimation based on a revised treatment effect and re-estimation based only on nuisance parameters (internal pilot designs). Finally, many logistical barriers must be overcome in order to use adaptive designs within existing trial frameworks.
If the promise of adaptive designs is to be achieved, it will be important to bring together large groups of individuals from funding sources and regulatory agencies to address these limitations. Very few discussions of these issues have appeared in journals that are targeted to clinical audiences. In fact, current use of adaptive designs is not really hindered by the lack of statistical methods to accommodate the adaptations. Rather, there is a need for education as to which adaptive designs are acceptable and which are not acceptable. These discussions will require the involvement of many individuals outside the statistical community. In this review, we summarize the existing methods and current controversies with the intent of providing a clarification that will enable these individuals to participate in these much-needed discussions.
Literature
1.
go back to reference Wittes J, Brittain E. The role of internal pilot studies in increasing the efficiency of clinical trials. Stat Med 1990; 9: 65–72PubMedCrossRef Wittes J, Brittain E. The role of internal pilot studies in increasing the efficiency of clinical trials. Stat Med 1990; 9: 65–72PubMedCrossRef
2.
go back to reference Gallo P, Chuang-Stein C, Dragalin V, et al. Adaptive designs in clinical drug development: an executive summary of the PhRMA working group. J Biopharm Stat 2006; 16: 275–83PubMedCrossRef Gallo P, Chuang-Stein C, Dragalin V, et al. Adaptive designs in clinical drug development: an executive summary of the PhRMA working group. J Biopharm Stat 2006; 16: 275–83PubMedCrossRef
3.
go back to reference Whitehead J, Zhou Y, Patterson S, et al. Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers. Biostatistics 2001; 2: 47–61PubMedCrossRef Whitehead J, Zhou Y, Patterson S, et al. Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers. Biostatistics 2001; 2: 47–61PubMedCrossRef
4.
go back to reference Krams M, Lees KR, Berry DA. The past is the future: innovative designs in acute stroke therapy trials. Stroke 2005; 36: 1341–7PubMedCrossRef Krams M, Lees KR, Berry DA. The past is the future: innovative designs in acute stroke therapy trials. Stroke 2005; 36: 1341–7PubMedCrossRef
5.
go back to reference Gaydos B, Krams M, Perevozskaya I, et al. Adaptive dose-response studies. Drug Inf J 2006; 40: 451–61 Gaydos B, Krams M, Perevozskaya I, et al. Adaptive dose-response studies. Drug Inf J 2006; 40: 451–61
6.
go back to reference Maca J, Bhattacharya S, Dragalin V, et al. Adaptive seamless phase II/III designs: background, operational aspects, and examples. Drug Inf J 2006; 40: 463–73 Maca J, Bhattacharya S, Dragalin V, et al. Adaptive seamless phase II/III designs: background, operational aspects, and examples. Drug Inf J 2006; 40: 463–73
7.
go back to reference Chow S, Chang M. Adaptive design methods in clinical trials. Boca Raton (FL): Chapman & Hall/CRC, 2007 Chow S, Chang M. Adaptive design methods in clinical trials. Boca Raton (FL): Chapman & Hall/CRC, 2007
8.
go back to reference Dragalin V. Adaptive designs: terminology and classification. Drug Inf J 2006; 40: 425–35 Dragalin V. Adaptive designs: terminology and classification. Drug Inf J 2006; 40: 425–35
9.
go back to reference Chang M. Adaptive design theory and implementation using SAS and R. Boca Raton (FL): Chapman & Hall/CRC, 2008 Chang M. Adaptive design theory and implementation using SAS and R. Boca Raton (FL): Chapman & Hall/CRC, 2008
11.
go back to reference O’Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 1990; 46: 33–48PubMedCrossRef O’Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 1990; 46: 33–48PubMedCrossRef
12.
go back to reference Garrett-Moyer E. The continual reassessment method for dose- finding studies: a tutorial. Clin Trials 2006; 3: 57–71CrossRef Garrett-Moyer E. The continual reassessment method for dose- finding studies: a tutorial. Clin Trials 2006; 3: 57–71CrossRef
13.
go back to reference Dougherty TB, Porche VH, Thall PF. Maximum tolerated dose of nalmefene in patients receiving epidural fentanyl and dilute bupivacaine for postoperative analgesia. Anesthesiology 2000; 92: 1010–6PubMedCrossRef Dougherty TB, Porche VH, Thall PF. Maximum tolerated dose of nalmefene in patients receiving epidural fentanyl and dilute bupivacaine for postoperative analgesia. Anesthesiology 2000; 92: 1010–6PubMedCrossRef
14.
go back to reference Desfrere L, Zohar S, Morville P, et al. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Ther 2005; 30: 121–32PubMedCrossRef Desfrere L, Zohar S, Morville P, et al. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Ther 2005; 30: 121–32PubMedCrossRef
15.
go back to reference Beloeil H, Eurin M, Thevenin A, et al. Effective dose of nefopam in 80% of patients (ED80): a study using the continual reassessment method. Br J Clin Pharmacol 2007; 64: 686–93PubMedCrossRef Beloeil H, Eurin M, Thevenin A, et al. Effective dose of nefopam in 80% of patients (ED80): a study using the continual reassessment method. Br J Clin Pharmacol 2007; 64: 686–93PubMedCrossRef
16.
go back to reference Thevenin A, Beloeil H, Blanie A, et al. The limited efficacy of tramadol in post-operative patients: a study of ED80 using the continual reassessment method. Anesth Analg 2008; 106: 622–7PubMedCrossRef Thevenin A, Beloeil H, Blanie A, et al. The limited efficacy of tramadol in post-operative patients: a study of ED80 using the continual reassessment method. Anesth Analg 2008; 106: 622–7PubMedCrossRef
17.
go back to reference Bornkamp B, Bretz F, Dmitrienko A, et al. Innovative approaches for designing and analyzing adaptive dose-ranging trials. J Biopharm Stat 2008; 17: 965–95CrossRef Bornkamp B, Bretz F, Dmitrienko A, et al. Innovative approaches for designing and analyzing adaptive dose-ranging trials. J Biopharm Stat 2008; 17: 965–95CrossRef
18.
go back to reference Berry DA, Mueller P, Grieve AP, et al. Bayesian designs for dose-ranging drug trials. In: Gatsonis C, Kass RE, Carlin B, et al., editors. Case studies in Bayesian statistics, Vol. 5. New York (NY): Springer-Verlag, 2002: 99–181CrossRef Berry DA, Mueller P, Grieve AP, et al. Bayesian designs for dose-ranging drug trials. In: Gatsonis C, Kass RE, Carlin B, et al., editors. Case studies in Bayesian statistics, Vol. 5. New York (NY): Springer-Verlag, 2002: 99–181CrossRef
19.
go back to reference Krams M, Lees KR, Hacke W, et al. ASTIN: an adaptive dose- response study of UK-279,276 in acute ischemic stroke. Stroke 2003; 34: 2543–9PubMedCrossRef Krams M, Lees KR, Hacke W, et al. ASTIN: an adaptive dose- response study of UK-279,276 in acute ischemic stroke. Stroke 2003; 34: 2543–9PubMedCrossRef
20.
go back to reference Levy G, Kaufmann P, Buchsbaum R, et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 2006; 66: 660–3PubMedCrossRef Levy G, Kaufmann P, Buchsbaum R, et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 2006; 66: 660–3PubMedCrossRef
21.
go back to reference Bretz F, Schmidli H, Koenig F, et al. Confirmatory seamless phase II/III clinical trials with hypothesis selection at interim: general concepts. Biom J 2006; 48 (4): 623–34PubMedCrossRef Bretz F, Schmidli H, Koenig F, et al. Confirmatory seamless phase II/III clinical trials with hypothesis selection at interim: general concepts. Biom J 2006; 48 (4): 623–34PubMedCrossRef
22.
go back to reference Bauer P, Kieser M. Combining different phases in development of medical treatments within a single trial. Stat Med 1999; 18: 1833–48PubMedCrossRef Bauer P, Kieser M. Combining different phases in development of medical treatments within a single trial. Stat Med 1999; 18: 1833–48PubMedCrossRef
23.
go back to reference Inoue LYT, Thall PF, Berry DA. Seamlessly expanding a randomized phase II trial to phase III. Biometrics 2002; 58: 823–31PubMedCrossRef Inoue LYT, Thall PF, Berry DA. Seamlessly expanding a randomized phase II trial to phase III. Biometrics 2002; 58: 823–31PubMedCrossRef
24.
go back to reference Bauer P, Kohne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50: 1029–41PubMedCrossRef Bauer P, Kohne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50: 1029–41PubMedCrossRef
25.
go back to reference Muller HH, Schafer H. Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and classical group sequential approaches. Biometrics 2001; 57: 886–91PubMedCrossRef Muller HH, Schafer H. Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and classical group sequential approaches. Biometrics 2001; 57: 886–91PubMedCrossRef
26.
go back to reference Ellenberg SS, Fleming TR, DeMets DL. Data monitoring committees in clinical trials: a practical perspective. Hoboken (NJ): John Wiley & Sons, 2003 Ellenberg SS, Fleming TR, DeMets DL. Data monitoring committees in clinical trials: a practical perspective. Hoboken (NJ): John Wiley & Sons, 2003
27.
go back to reference Proschan MA, Lan KKG, Wittes J. Statistical monitoring of clinical trials: a unified approach. New York (NY): Springer, 2006 Proschan MA, Lan KKG, Wittes J. Statistical monitoring of clinical trials: a unified approach. New York (NY): Springer, 2006
28.
go back to reference Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials. Boca Raton (FL): Chapman & Hall/ CRC, 2000 Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials. Boca Raton (FL): Chapman & Hall/ CRC, 2000
29.
go back to reference Rosenberger WF, Lachin J. Randomization in clinical trials. New York (NY): John Wiley & Sons, 2002CrossRef Rosenberger WF, Lachin J. Randomization in clinical trials. New York (NY): John Wiley & Sons, 2002CrossRef
30.
go back to reference Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis 1974; 28: 365–75CrossRef Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis 1974; 28: 365–75CrossRef
31.
go back to reference Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 1975; 31: 103–15PubMedCrossRef Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 1975; 31: 103–15PubMedCrossRef
32.
go back to reference Wei LJ, Durham S. The randomized play-the-winner rule in medical trials. J Am Stat Assoc 1978; 73: 840–843CrossRef Wei LJ, Durham S. The randomized play-the-winner rule in medical trials. J Am Stat Assoc 1978; 73: 840–843CrossRef
33.
go back to reference Hardwick JP, Stout QF. Bandit strategies for ethical sequential allocation. Computing Science Stat 1991; 23: 421–4 Hardwick JP, Stout QF. Bandit strategies for ethical sequential allocation. Computing Science Stat 1991; 23: 421–4
34.
go back to reference Coad DS, Rosenberger WF. A comparison of the randomized play-the-winner and the triangular test for clinical trials with binary responses. Stat Med 1999; 18: 761–9PubMedCrossRef Coad DS, Rosenberger WF. A comparison of the randomized play-the-winner and the triangular test for clinical trials with binary responses. Stat Med 1999; 18: 761–9PubMedCrossRef
35.
go back to reference Bartlett RH, Roloff DW, Cornell RG, et al. Extracorporeal circulation in neonatal respiratory failure: a prospective ran-domized study. Pediatrics 1985; 76: 479–87PubMed Bartlett RH, Roloff DW, Cornell RG, et al. Extracorporeal circulation in neonatal respiratory failure: a prospective ran-domized study. Pediatrics 1985; 76: 479–87PubMed
36.
go back to reference Freedman KB, Bernstein J. Sample size and statistical power in clinical orthopaedic research. J Bone Joint Surgery 1999; 81: 1454–60 Freedman KB, Bernstein J. Sample size and statistical power in clinical orthopaedic research. J Bone Joint Surgery 1999; 81: 1454–60
37.
go back to reference Dickinson K, Bunn F, Wentz R, et al. Size and quality of randomized controlled trials in head injury: review of published studies. BMJ 2000; 320: 1308–11PubMedCrossRef Dickinson K, Bunn F, Wentz R, et al. Size and quality of randomized controlled trials in head injury: review of published studies. BMJ 2000; 320: 1308–11PubMedCrossRef
38.
go back to reference Samsa GP, Matchar DB. Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles. Stroke 2001; 32: 669–74PubMedCrossRef Samsa GP, Matchar DB. Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles. Stroke 2001; 32: 669–74PubMedCrossRef
39.
40.
go back to reference Maxwell SE. The persistence of underpowered studies in psychological research: causes, consequences, and remedies. Psychol Methods 2004; 9: 147–63PubMedCrossRef Maxwell SE. The persistence of underpowered studies in psychological research: causes, consequences, and remedies. Psychol Methods 2004; 9: 147–63PubMedCrossRef
41.
go back to reference Wakelee H, Dubey S, Gandara D. Optimal adjuvant therapy for non-small cell lung cancer: how to handle stage I disease. Oncologist 2007; 12: 331–7PubMedCrossRef Wakelee H, Dubey S, Gandara D. Optimal adjuvant therapy for non-small cell lung cancer: how to handle stage I disease. Oncologist 2007; 12: 331–7PubMedCrossRef
42.
go back to reference Bedard PL, Krzyanowska MK, Pintilie M, et al. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings. J Clin Oncol 2007; 25: 3482–6PubMedCrossRef Bedard PL, Krzyanowska MK, Pintilie M, et al. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings. J Clin Oncol 2007; 25: 3482–6PubMedCrossRef
43.
go back to reference Edwards SJL, Lilford RJ, Braunholtz D, et al. Why ‘underpowered’ trials are not necessarily unethical. Lancet 1997; 350: 804–7PubMedCrossRef Edwards SJL, Lilford RJ, Braunholtz D, et al. Why ‘underpowered’ trials are not necessarily unethical. Lancet 1997; 350: 804–7PubMedCrossRef
44.
go back to reference Bachetti P, Wolf LE, Segal MR, et al. Ethics and sample size. Am J Epidemiol 2005; 161: 105–10CrossRef Bachetti P, Wolf LE, Segal MR, et al. Ethics and sample size. Am J Epidemiol 2005; 161: 105–10CrossRef
45.
go back to reference Halpern S, Karlawish JHT, Berlin JA. The continuing unethical conduct of underpowered trials. JAMA 2002; 288: 358–62PubMedCrossRef Halpern S, Karlawish JHT, Berlin JA. The continuing unethical conduct of underpowered trials. JAMA 2002; 288: 358–62PubMedCrossRef
46.
go back to reference Bäuer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50: 1029–41PubMedCrossRef Bäuer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50: 1029–41PubMedCrossRef
47.
go back to reference Proschan MA, Hunsberger SA. Designed extension of studies based on conditional power. Biometrics 1995; 51: 1315–24PubMedCrossRef Proschan MA, Hunsberger SA. Designed extension of studies based on conditional power. Biometrics 1995; 51: 1315–24PubMedCrossRef
49.
go back to reference Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics 1999; 55: 1286–90PubMedCrossRef Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics 1999; 55: 1286–90PubMedCrossRef
50.
go back to reference Cui L, Hung HMJ, Wang S. Modification of sample size in group sequential clinical trials. Biometrics 1999; 55: 853–7PubMedCrossRef Cui L, Hung HMJ, Wang S. Modification of sample size in group sequential clinical trials. Biometrics 1999; 55: 853–7PubMedCrossRef
51.
go back to reference Müller H, Schäfer H. Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches. Biometrics 2001; 57: 886–91PubMedCrossRef Müller H, Schäfer H. Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches. Biometrics 2001; 57: 886–91PubMedCrossRef
52.
53.
go back to reference Mehta CR, Patel NR. Adaptive, group sequential, and decision theoretic approaches to sample size determination. Stat Med 2006; 25: 3250–69PubMedCrossRef Mehta CR, Patel NR. Adaptive, group sequential, and decision theoretic approaches to sample size determination. Stat Med 2006; 25: 3250–69PubMedCrossRef
54.
go back to reference Tsiatis AA, Mehta C. On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika 2003; 90: 367–78CrossRef Tsiatis AA, Mehta C. On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika 2003; 90: 367–78CrossRef
55.
go back to reference Jennison C, Turnbull BW. Efficient group sequential designs when there are several effect sizes under consideration. Stat Med 2006; 25: 917–32PubMedCrossRef Jennison C, Turnbull BW. Efficient group sequential designs when there are several effect sizes under consideration. Stat Med 2006; 25: 917–32PubMedCrossRef
56.
go back to reference Herson J, Wittes J. The use of interim analysis in sample size adjustment. Drug Inf J 1993; 27: 753–60CrossRef Herson J, Wittes J. The use of interim analysis in sample size adjustment. Drug Inf J 1993; 27: 753–60CrossRef
57.
go back to reference Gould AL. Interim analyses for monitoring clinical trials that do not materially affect the type I error rate. Stat Med 1992; 11: 55–66PubMedCrossRef Gould AL. Interim analyses for monitoring clinical trials that do not materially affect the type I error rate. Stat Med 1992; 11: 55–66PubMedCrossRef
58.
go back to reference Bolland K, Sooriyarachchi MR, Whitehead J. Sample size review in a head injury trial with ordered categorical responses. Stat Med 1998; 17: 2835–47PubMedCrossRef Bolland K, Sooriyarachchi MR, Whitehead J. Sample size review in a head injury trial with ordered categorical responses. Stat Med 1998; 17: 2835–47PubMedCrossRef
59.
go back to reference Whitehead J, Whitehead A, Todd S, et al. Mid-trial design reviews for sequential clinical trials. Stat Med 2001; 20: 165–76PubMedCrossRef Whitehead J, Whitehead A, Todd S, et al. Mid-trial design reviews for sequential clinical trials. Stat Med 2001; 20: 165–76PubMedCrossRef
60.
go back to reference Coffey CS, Muller KE. Exact test size and power of a Gaussian error linear model for an internal pilot study. Stat Med 1999; 18: 1199–214PubMedCrossRef Coffey CS, Muller KE. Exact test size and power of a Gaussian error linear model for an internal pilot study. Stat Med 1999; 18: 1199–214PubMedCrossRef
61.
go back to reference Coffey CS, Muller KE. Controlling test size while gaining the benefits of an internal pilot design. Biometrics 2001; 57: 625–31PubMedCrossRef Coffey CS, Muller KE. Controlling test size while gaining the benefits of an internal pilot design. Biometrics 2001; 57: 625–31PubMedCrossRef
62.
go back to reference Coffey CS, Kairalla JA, Muller KE. Practical methods for bounding type I error rate with an internal pilot design. Comm Stat Theory Methods 2007; 36: 2143–57CrossRef Coffey CS, Kairalla JA, Muller KE. Practical methods for bounding type I error rate with an internal pilot design. Comm Stat Theory Methods 2007; 36: 2143–57CrossRef
63.
go back to reference Shih WJ, Gould AL. Re-evaluating design specifications of longitudinal clinical trials without unblinding when the key response is rate of change. Stat Med 1995; 14: 2239–48PubMedCrossRef Shih WJ, Gould AL. Re-evaluating design specifications of longitudinal clinical trials without unblinding when the key response is rate of change. Stat Med 1995; 14: 2239–48PubMedCrossRef
64.
go back to reference Lake S, Kammann E, Klar N, et al. Sample size re-estimation in cluster randomization trials. Stat Med 2002; 21: 1337–50PubMedCrossRef Lake S, Kammann E, Klar N, et al. Sample size re-estimation in cluster randomization trials. Stat Med 2002; 21: 1337–50PubMedCrossRef
65.
go back to reference Zucker DM, Denne J. Sample size re-determination for repeated measures studies. Biometrics 2002; 58: 548–59PubMedCrossRef Zucker DM, Denne J. Sample size re-determination for repeated measures studies. Biometrics 2002; 58: 548–59PubMedCrossRef
66.
go back to reference Coffey CS, Muller KE. Properties of internal pilots with the univariate approach to repeated measures. Stat Med 2003; 22: 2469–85PubMedCrossRef Coffey CS, Muller KE. Properties of internal pilots with the univariate approach to repeated measures. Stat Med 2003; 22: 2469–85PubMedCrossRef
67.
go back to reference Gurka MJ, Coffey CS, Muller KE. Internal pilots for a class of linear mixed models with Gaussian and compound symmetric data. Stat Med 2007; 26: 4083–99PubMedCrossRef Gurka MJ, Coffey CS, Muller KE. Internal pilots for a class of linear mixed models with Gaussian and compound symmetric data. Stat Med 2007; 26: 4083–99PubMedCrossRef
68.
go back to reference Proschan MA. Two-stage sample size re-estimation based on a nuisance parameter: a review. J Biopharm Stat 2005; 15: 559–74PubMedCrossRef Proschan MA. Two-stage sample size re-estimation based on a nuisance parameter: a review. J Biopharm Stat 2005; 15: 559–74PubMedCrossRef
69.
go back to reference Friede T, Kieser M. Sample size recalculation in internal pilot study designs: a review. Biom J 2006; 4: 537–55CrossRef Friede T, Kieser M. Sample size recalculation in internal pilot study designs: a review. Biom J 2006; 4: 537–55CrossRef
71.
go back to reference Gould AL, Shih W. Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance. Comm Stat Theory Methods 1992; 21: 2833–53CrossRef Gould AL, Shih W. Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance. Comm Stat Theory Methods 1992; 21: 2833–53CrossRef
72.
go back to reference Denne JS, Jennison C. Estimating the sample size for a t-test using an internal pilot. Stat Med 1999; 18: 1575–85PubMedCrossRef Denne JS, Jennison C. Estimating the sample size for a t-test using an internal pilot. Stat Med 1999; 18: 1575–85PubMedCrossRef
73.
go back to reference Zucker DM, Wittes JT, Schabenberger O, et al. Internal pilot studies. II: comparison of various procedures. Stat Med 1999; 18: 3493–509PubMedCrossRef Zucker DM, Wittes JT, Schabenberger O, et al. Internal pilot studies. II: comparison of various procedures. Stat Med 1999; 18: 3493–509PubMedCrossRef
74.
go back to reference Kieser M, Friede T. Re-calculating the sample size in internal pilot study designs with control of the type I error rate. Stat Med 2000; 19: 901–11PubMedCrossRef Kieser M, Friede T. Re-calculating the sample size in internal pilot study designs with control of the type I error rate. Stat Med 2000; 19: 901–11PubMedCrossRef
75.
go back to reference Proschan MA, Wittes J. An improved double sampling procedure based on the variance. Biometrics 2000; 56: 1183–7PubMedCrossRef Proschan MA, Wittes J. An improved double sampling procedure based on the variance. Biometrics 2000; 56: 1183–7PubMedCrossRef
76.
go back to reference Kieser M, Friede T. Simple procedures for blinded sample size adjustment that do not affect the type I error rate. Stat Med 2003; 22: 3571–81PubMedCrossRef Kieser M, Friede T. Simple procedures for blinded sample size adjustment that do not affect the type I error rate. Stat Med 2003; 22: 3571–81PubMedCrossRef
77.
go back to reference Miller F. Variance estimation in clinical studies with interim sample size re-estimation. Biometrics 2005; 61: 355–61PubMedCrossRef Miller F. Variance estimation in clinical studies with interim sample size re-estimation. Biometrics 2005; 61: 355–61PubMedCrossRef
78.
go back to reference ICH Guideline E9. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH Topic E9: statistical principles for clinical trials. London: ICH Technical Coordination, EMEA, 1998 ICH Guideline E9. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH Topic E9: statistical principles for clinical trials. London: ICH Technical Coordination, EMEA, 1998
79.
go back to reference Bauer P, Einfalt J. Application of adaptive designs: a review. Biometric J 2006; 4: 493–506CrossRef Bauer P, Einfalt J. Application of adaptive designs: a review. Biometric J 2006; 4: 493–506CrossRef
80.
go back to reference Tharmanathan P, Calvert M, Hampton J, et al. The use of interim data and data monitoring committee recommendations in randomized controlled trial reports: frequency, implications, and potential sources of bias. BMC Med Res Methodol 2008; 8: 12PubMedCrossRef Tharmanathan P, Calvert M, Hampton J, et al. The use of interim data and data monitoring committee recommendations in randomized controlled trial reports: frequency, implications, and potential sources of bias. BMC Med Res Methodol 2008; 8: 12PubMedCrossRef
81.
go back to reference Hersey P, Coates AS, McCarthy WH, et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 2002; 20: 4181–90PubMedCrossRef Hersey P, Coates AS, McCarthy WH, et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 2002; 20: 4181–90PubMedCrossRef
82.
go back to reference To MS, Alfirevic Z, Heath VCF, et al. Cervical cerclage for prevention of preterm delivery in women with short cervix: randomised controlled trial. Lancet 2004; 363: 1849–53PubMedCrossRef To MS, Alfirevic Z, Heath VCF, et al. Cervical cerclage for prevention of preterm delivery in women with short cervix: randomised controlled trial. Lancet 2004; 363: 1849–53PubMedCrossRef
83.
go back to reference Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967–77PubMedCrossRef Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967–77PubMedCrossRef
84.
go back to reference Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease — the International Verapamil-Trandolapril Study (INVEST): a ran-domized controlled trial. JAMA 2003; 290: 2805–16PubMedCrossRef Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease — the International Verapamil-Trandolapril Study (INVEST): a ran-domized controlled trial. JAMA 2003; 290: 2805–16PubMedCrossRef
85.
go back to reference Kirby S, McBride S, Puvanarajan L. An example of an unblended, third-party interim analysis for sample size re-estimation. Drug Inf J 2003; 37: 317–20CrossRef Kirby S, McBride S, Puvanarajan L. An example of an unblended, third-party interim analysis for sample size re-estimation. Drug Inf J 2003; 37: 317–20CrossRef
86.
go back to reference Mehta CR, Tsiatis AA. Flexible sample size considerations using information based monitoring. Drug Inf J 2001; 35: 1095–112CrossRef Mehta CR, Tsiatis AA. Flexible sample size considerations using information based monitoring. Drug Inf J 2001; 35: 1095–112CrossRef
87.
88.
go back to reference Kairalla JA. An internal pilot study with interim analysis for Gaussian linear models [dissertation]. Chapel Hill (NC): University of North Carolina at Chapel Hill, 2007 Kairalla JA. An internal pilot study with interim analysis for Gaussian linear models [dissertation]. Chapel Hill (NC): University of North Carolina at Chapel Hill, 2007
89.
go back to reference Quinlan JA, Krams M. Implementing adaptive designs: logistical and operational considerations. Drug Inf J 2006; 40 (6): 437–44 Quinlan JA, Krams M. Implementing adaptive designs: logistical and operational considerations. Drug Inf J 2006; 40 (6): 437–44
90.
go back to reference Hung HMJ, O’Neill RT, Wang SJ, et al. A regulatory view on adaptive/flexible clinical trial design. Biom J 2006; 3: 1–9 Hung HMJ, O’Neill RT, Wang SJ, et al. A regulatory view on adaptive/flexible clinical trial design. Biom J 2006; 3: 1–9
91.
go back to reference Fisher MR, Roecker EB, Demets DL. The role of an independent statistical analysis center in the industry-modified National Institutes of Health model. Drug Inf J 2001; 35: 115–29CrossRef Fisher MR, Roecker EB, Demets DL. The role of an independent statistical analysis center in the industry-modified National Institutes of Health model. Drug Inf J 2001; 35: 115–29CrossRef
92.
go back to reference Bryant J. What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent data monitoring committee in the U.S. Cancer Cooperative Group setting? Stat Med 2004; 23: 1507–11PubMedCrossRef Bryant J. What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent data monitoring committee in the U.S. Cancer Cooperative Group setting? Stat Med 2004; 23: 1507–11PubMedCrossRef
93.
94.
go back to reference Ellenberg SS, George SL. Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership? Stat Med 2004; 23: 1503–5PubMedCrossRef Ellenberg SS, George SL. Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership? Stat Med 2004; 23: 1503–5PubMedCrossRef
95.
96.
go back to reference Snappin S, Cook T, Shapiro D, et al. The role of the unblinded sponsor statistician. Stat Med 2004; 23: 1531–3CrossRef Snappin S, Cook T, Shapiro D, et al. The role of the unblinded sponsor statistician. Stat Med 2004; 23: 1531–3CrossRef
97.
go back to reference Wittes J. Playing safe and preserving integrity: making the FDA model work. Stat Med 2004; 23: 1523–5PubMedCrossRef Wittes J. Playing safe and preserving integrity: making the FDA model work. Stat Med 2004; 23: 1523–5PubMedCrossRef
98.
go back to reference Coffey CS, Muller KE. GLUMIP 1.0: Free SAS/IML software for internal pilots. 2001 Proceedings of the Joint Statistical Meetings, Biopharmaceutical Section [CD-ROM] Coffey CS, Muller KE. GLUMIP 1.0: Free SAS/IML software for internal pilots. 2001 Proceedings of the Joint Statistical Meetings, Biopharmaceutical Section [CD-ROM]
99.
go back to reference EMEA. Report on the EMEA-EFPIA workshop on adaptive designs in confirmatory clinical trials. European Medicines Agency 2008, EMEA/106659/2008 EMEA. Report on the EMEA-EFPIA workshop on adaptive designs in confirmatory clinical trials. European Medicines Agency 2008, EMEA/106659/2008
Metadata
Title
Adaptive Clinical Trials
Progress and Challenges
Authors
Dr Christopher S. Coffey
John A. Kairalla
Publication date
01-07-2008
Publisher
Springer International Publishing
Published in
Drugs in R&D / Issue 4/2008
Print ISSN: 1174-5886
Electronic ISSN: 1179-6901
DOI
https://doi.org/10.2165/00126839-200809040-00003

Other articles of this Issue 4/2008

Drugs in R&D 4/2008 Go to the issue

Adis R&D Profile

Aflibercept

Leading Article

Systems Biology